NYSE:CRL - Charles River Laboratories International Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $381.00
  • Forecasted Upside: 74.11 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$218.83
▲ +4.86 (2.27%)

This chart shows the closing price for CRL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Charles River Laboratories International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRL

Analyst Price Target is $381.00
▲ +74.11% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Charles River Laboratories International in the last 3 months. The average price target is $381.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 74.11% upside from the last price of $218.83.

This chart shows the closing price for CRL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 polled investment analysts is to buy stock in Charles River Laboratories International. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/20/2022StephensSet Price Target$315.00Low
5/23/2022GuggenheimInitiated CoverageNeutralHigh
5/5/2022KeyCorpLower Price Target$390.00 ➝ $300.00High
4/25/2022Wells Fargo & CompanyLower Price TargetOverweight$390.00 ➝ $325.00High
4/25/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$370.00 ➝ $280.00High
4/6/2022StephensInitiated CoverageOverweight$377.00High
2/17/2022Bank of AmericaLower Price TargetBuy$445.00 ➝ $400.00High
2/17/2022UBS GroupLower Price TargetBuy$465.00 ➝ $420.00High
2/17/2022Morgan StanleyLower Price TargetOverweight$465.00 ➝ $430.00High
2/17/2022Wells Fargo & CompanyLower Price Target$450.00 ➝ $390.00High
2/17/2022Deutsche Bank AktiengesellschaftLower Price TargetBuy$409.00 ➝ $350.00High
2/17/2022CitigroupUpgradeNeutral ➝ Buy$400.00High
2/17/2022KeyCorpLower Price TargetOverweight$450.00 ➝ $390.00High
12/20/2021Robert W. BairdReiterated RatingBuyHigh
11/16/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$354.00 ➝ $409.00Medium
11/12/2021Robert W. BairdReiterated RatingBuy$452.00Low
11/4/2021Morgan StanleyLower Price TargetOverweight$480.00 ➝ $465.00Low
11/4/2021CitigroupLower Price TargetNeutral$425.00 ➝ $400.00High
10/14/2021Evercore ISIReiterated RatingBuyMedium
8/23/2021ArgusBoost Price TargetBuy$390.00 ➝ $480.00Medium
8/17/2021UBS GroupBoost Price TargetBuy$390.00 ➝ $465.00Low
8/5/2021Credit Suisse GroupBoost Price TargetNeutral$385.00 ➝ $420.00Medium
8/5/2021Wells Fargo & CompanyBoost Price TargetOverweight$375.00 ➝ $470.00Medium
8/5/2021Robert W. BairdBoost Price TargetOutperform$410.00 ➝ $461.00Medium
7/20/2021Credit Suisse GroupBoost Price TargetNeutral$352.00 ➝ $385.00High
5/31/2021Robert W. BairdReiterated RatingBuyMedium
5/28/2021Credit Suisse GroupBoost Price TargetNeutral$342.00 ➝ $352.00Low
5/28/2021JPMorgan Chase & Co.Boost Price TargetPositive ➝ Overweight$375.00 ➝ $390.00Medium
5/28/2021CitigroupBoost Price TargetNeutral$350.00 ➝ $355.00Medium
5/25/2021Truist FinancialBoost Price TargetBuy$324.00 ➝ $369.00Medium
5/14/2021KeyCorpBoost Price TargetOverweight$340.00 ➝ $360.00High
5/5/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$334.00 ➝ $354.00Medium
5/5/2021Robert W. BairdBoost Price TargetOutperform$338.00 ➝ $400.00Medium
2/25/2021Morgan StanleyBoost Price TargetOverweight$280.00 ➝ $350.00Medium
2/18/2021Truist FinancialBoost Price Target$256.00 ➝ $324.00Medium
2/18/2021Credit Suisse GroupBoost Price TargetNeutral$259.00 ➝ $301.00High
2/18/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$250.00 ➝ $334.00High
12/22/2020ArgusBoost Price TargetBuy$235.00 ➝ $265.00Low
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ NeutralLow
11/24/2020KeyCorpBoost Price TargetOverweight$233.00 ➝ $256.00High
11/3/2020Truist FinancialBoost Price Target$237.00 ➝ $256.00Low
10/30/2020Morgan StanleyBoost Price TargetOverweight$245.00 ➝ $260.00Medium
10/30/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$235.00 ➝ $250.00Medium
9/14/2020ArgusBoost Price TargetBuy$190.00 ➝ $235.00Low
9/10/2020Jefferies Financial GroupUpgradeHold ➝ Buy$213.00 ➝ $254.00High
8/18/2020KeyCorpBoost Price TargetOverweight$186.00 ➝ $233.00Low
8/6/2020Morgan StanleyBoost Price TargetOverweight$175.00 ➝ $245.00Low
8/6/2020CitigroupBoost Price TargetBuy$190.00 ➝ $255.00Low
7/21/2020UBS GroupBoost Price TargetBuy$200.00 ➝ $236.00Low
7/1/2020Bank of AmericaUpgradeNeutral ➝ Buy$192.00Low
5/26/2020ArgusBoost Price TargetAverage ➝ Buy$150.00 ➝ $190.00Medium
5/13/2020UBS GroupUpgradeNeutral ➝ Buy$177.00 ➝ $200.00Low
5/12/2020Deutsche Bank AktiengesellschaftLower Price TargetBuy$190.00 ➝ $174.00Medium
5/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$160.00 ➝ $180.00Low
5/8/2020Robert W. BairdBoost Price TargetOutperform$156.00 ➝ $175.00Low
5/8/2020Credit Suisse GroupLower Price TargetNeutral$162.00 ➝ $159.00Low
5/8/2020Morgan StanleyBoost Price TargetOverweight$152.00 ➝ $175.00Medium
5/8/2020CitigroupBoost Price TargetBuy$165.00 ➝ $190.00Medium
5/8/2020SunTrust BanksBoost Price TargetBuy$130.00 ➝ $194.00Medium
4/21/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$139.00High
4/9/2020CitigroupLower Price TargetBuy$200.00 ➝ $165.00Medium
4/6/2020SunTrust BanksBoost Price TargetBuy$124.00 ➝ $130.00High
3/30/2020Wells Fargo & CompanyLower Price TargetOverweight$200.00 ➝ $145.00High
3/27/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$152.00High
3/26/2020BarclaysLower Price TargetEqual Weight$170.00 ➝ $154.00High
3/23/2020Jefferies Financial GroupLower Price TargetBuy$200.00 ➝ $139.00Medium
3/17/2020SunTrust BanksLower Price TargetBuy$188.00 ➝ $124.00High
3/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$190.00High
2/18/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$169.00 ➝ $203.00Low
2/12/2020Morgan StanleyBoost Price TargetEqual Weight$156.00 ➝ $176.00Medium
2/12/2020Robert W. BairdReiterated RatingOutperform$165.00 ➝ $185.00Medium
2/12/2020BarclaysReiterated RatingHold$170.00Low
2/12/2020CitigroupBoost Price TargetBuy$185.00 ➝ $200.00Low
2/11/2020CfraBoost Price TargetStrong-Buy$165.00 ➝ $180.00Medium
1/10/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$143.00 ➝ $179.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$180.00Low
1/6/2020CitigroupInitiated CoverageBuy$185.00Low
12/17/2019Robert W. BairdBoost Price TargetOutperform$160.00 ➝ $165.00Medium
12/9/2019KeyCorpBoost Price TargetOverweight ➝ Overweight$151.00 ➝ $162.00Medium
11/19/2019ArgusReiterated RatingBuy$170.00Low
10/18/2019Bank of AmericaDowngradeBuy ➝ Neutral$150.00High
9/16/2019SunTrust BanksBoost Price TargetBuy ➝ Buy$156.00 ➝ $162.00Medium
9/13/2019Credit Suisse GroupSet Price TargetHold$138.00Medium
6/10/2019SVB LeerinkInitiated CoverageOutperform$155.00Low
4/30/2019Evercore ISIReiterated RatingOutperform ➝ Outperform$160.00Low
4/2/2019Wolfe ResearchInitiated CoverageMarket PerformMedium
3/18/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$135.00 ➝ $145.00Medium
3/11/2019KeyCorpBoost Price TargetOverweight ➝ Overweight$140.00 ➝ $151.00Low
2/14/2019BarclaysReiterated RatingHold$135.00Low
2/14/2019SunTrust BanksBoost Price TargetPositive ➝ Buy$151.00Low
2/14/2019Jefferies Financial GroupReiterated RatingBuy$162.00Low
12/14/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ BuyLow
12/4/2018Raymond JamesReiterated RatingBuy$150.00Low
12/3/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$112.00 ➝ $136.00Low
11/8/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$144.00 ➝ $148.00Medium
11/8/2018Raymond JamesBoost Price TargetOutperform ➝ Buy$140.00 ➝ $150.00Medium
11/7/2018Royal Bank of CanadaSet Price TargetOutperform ➝ Buy$131.00 ➝ $147.00N/A
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$140.00Low
9/25/2018Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$121.00 ➝ $128.00High
9/17/2018Robert W. BairdBoost Price TargetOutperform$133.00 ➝ $141.00Low
9/11/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Hold$102.00 ➝ $112.00Low
8/27/2018ArgusBoost Price TargetBuy ➝ Buy$125.00 ➝ $140.00Low
8/23/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$140.00Medium
8/21/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$129.00 ➝ $121.00Low
8/9/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$110.00 ➝ $120.00Medium
8/9/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$140.00 ➝ $145.00High
8/9/2018SunTrust BanksBoost Price TargetBuy$135.00Medium
7/20/2018Jefferies Financial GroupReiterated RatingBuy$140.00Low
7/17/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$131.00High
7/16/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$120.00 ➝ $125.00Low
6/15/2018KeyCorpUpgradeSector Weight ➝ Overweight$115.85 ➝ $130.00High
4/20/2018Mitsubishi UFJ Financial GroupInitiated CoverageNeutral$115.00Low
3/14/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$94.00 ➝ $102.00Low
2/16/2018BarclaysReiterated RatingHold$110.00Low
2/15/2018Credit Suisse GroupReiterated RatingHold$108.00Low
2/14/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$110.00 ➝ $120.00Medium
2/14/2018SunTrust BanksUpgradeHold ➝ Buy$107.66 ➝ $125.00Medium
2/13/2018Royal Bank of CanadaSet Price TargetHold$116.00High
2/13/2018Robert W. BairdSet Price TargetBuy$123.00High
1/22/2018SunTrust BanksDowngradeBuy ➝ Hold$107.89 ➝ $111.00Medium
1/18/2018Evercore ISIInitiated CoverageIn ➝ In-Line$117.00Low
12/13/2017ArgusInitiated CoverageBuy ➝ Buy$120.00Medium
11/17/2017SunTrust BanksReiterated RatingBuy$113.00N/A
11/13/2017Robert W. BairdSet Price TargetBuy$117.00N/A
11/10/2017Bank of AmericaLower Price TargetBuy$117.00 ➝ $115.00N/A
10/16/2017Credit Suisse GroupReiterated RatingNeutral$95.00 ➝ $112.00N/A
10/9/2017Jefferies Financial GroupBoost Price TargetBuy$120.00 ➝ $130.00N/A
9/19/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$110.00Medium
9/12/2017Jefferies Financial GroupReiterated RatingBuy$120.00Low
9/1/2017Robert W. BairdReiterated RatingBuy$114.00Low
7/19/2017BarclaysReiterated RatingHold$102.00Low
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 5 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/7/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/6/2022
  • 2 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Charles River Laboratories International logo
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More

Today's Range

Now: $218.83
Low: $214.06
High: $219.54

50 Day Range

MA: $228.96
Low: $204.13
High: $257.51

52 Week Range

Now: $218.83
Low: $203.37
High: $460.21

Volume

9,713 shs

Average Volume

538,704 shs

Market Capitalization

$11.12 billion

P/E Ratio

26.65

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Charles River Laboratories International?

The following sell-side analysts have issued research reports on Charles River Laboratories International in the last year: Argus, Bank of America Co., Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, Jefferies Financial Group Inc., KeyCorp, Morgan Stanley, Robert W. Baird, Stephens, StockNews.com, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for CRL.

What is the current price target for Charles River Laboratories International?

0 Wall Street analysts have set twelve-month price targets for Charles River Laboratories International in the last year. Their average twelve-month price target is $381.00, suggesting a possible upside of 74.1%.
View the latest price targets for CRL.

What is the current consensus analyst rating for Charles River Laboratories International?

Charles River Laboratories International currently has 3 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRL will outperform the market and that investors should add to their positions of Charles River Laboratories International.
View the latest ratings for CRL.

What other companies compete with Charles River Laboratories International?

How do I contact Charles River Laboratories International's investor relations team?

Charles River Laboratories International's physical mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company's listed phone number is (781) 222-6000 and its investor relations email address is [email protected] The official website for Charles River Laboratories International is www.criver.com. Learn More about contacing Charles River Laboratories International investor relations.